Milestone Pharmaceuticals

1. etripamil AFib-RVR Ph3 start2H 2026etripamil AFib-RVR Ph3 start, 2H 2026, routine
2. ReVeRA-301 Ph3 start2H 2026ReVeRA-301 Ph3 start, 2H 2026, routine
3. CARDAMYST etripamil FDA approval1H 2027CARDAMYST etripamil FDA approval, 1H 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.